Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/181451
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Smith, Graham | - |
dc.contributor.author | Henry, W. Keith | - |
dc.contributor.author | Podzamczer Palter, Daniel | - |
dc.contributor.author | Masiá, Maria Del Mar | - |
dc.contributor.author | Bettacchi, Christopher J. | - |
dc.contributor.author | Arasteh, Keikawus | - |
dc.contributor.author | Jaeger, Hans | - |
dc.contributor.author | Khuong-Josses, Marie-Aude | - |
dc.contributor.author | Montes, Maria Luisa | - |
dc.contributor.author | Stellbrink, Hans-jürgen | - |
dc.contributor.author | Yazdanpanah, Yazdan | - |
dc.contributor.author | Richmond, Gary J. | - |
dc.contributor.author | Sutton, Kenneth C. | - |
dc.contributor.author | Zhang, Feifan | - |
dc.contributor.author | Mccoig, Cynthia C. | - |
dc.contributor.author | St. Clair, Marty H. | - |
dc.contributor.author | Vandermeulen, Kati | - |
dc.contributor.author | Van Solingen-Ristea, Rodica | - |
dc.contributor.author | Smith, Kimberly Y. | - |
dc.contributor.author | Margolis, David A. | - |
dc.contributor.author | Spreen, William R. | - |
dc.date.accessioned | 2021-11-25T12:16:34Z | - |
dc.date.available | 2021-11-25T12:16:34Z | - |
dc.date.issued | 2021-08-25 | - |
dc.identifier.uri | http://hdl.handle.net/2445/181451 | - |
dc.description.abstract | Background. In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b study, long-acting (LA) injectable cabotegravir + rilpivirine dosed every 8 weeks (Q8W) or every 4 weeks (Q4W) demonstrated comparable efficacy with daily oral antiretroviral therapy (ART) through 96 weeks in ART-naive adults with human immunodeficiency virus type 1 (HIV-1). Here we report efficacy, tolerability, and safety of cabotegravir + rilpivirine LA over approximately 5 years. Methods. After 20 weeks of oral cabotegravir + abacavir/lamivudine, participants were randomized to cabotegravir + rilpivirine LA Q8W or Q4W or continue oral ART through the 96-week maintenance period. In the extension period through week 256, participants continued their current LA regimen (randomized Q8W/Q4W groups) or switched from oral ART to Q8W or Q4W LA therapy (extension-switch groups). Endpoints assessed included proportion of participants with HIV-1 RNA <50 copies/mL (Snapshot algorithm) and adverse events (AEs). Results. At week 256, 186 of 230 (81%) participants in randomized Q8W/Q4W groups and 41 of 44 (93%) participants in extension-switch groups had HIV-1 RNA <50 copies/mL. No protocol-defined virologic failures occurred after week 48. Injection wsite reactions infrequently resulted in discontinuation (4 [2%] and 1 [2%] participants in randomized Q8W/Q4W and extension-switch groups, respectively). Three participants in randomized Q8W/Q4W groups experienced drug-related serious AEs, including 1 fatal serious AE (Q4W group); none occurred in extension-switch groups. Of 25 participants with AEs leading to withdrawal, 20 were in the randomized Q4W group; no AE leading to withdrawal occurred in >1 participant. Conclusions. Cabotegravir + rilpivirine LA exhibited long-term efficacy and tolerability, demonstrating its durability as maintenance therapy for HIV-1 infection. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Oxford University Press | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1093/ofid/ofab439 | - |
dc.relation.ispartof | Open Forum Infectious Diseases, 2021, vol. 8, issue. 9 | - |
dc.relation.uri | https://doi.org/10.1093/ofid/ofab439 | - |
dc.rights | cc-by-nc-nd (c) Smith, Graham et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Inhibidors de la integrasa | - |
dc.subject.classification | Nucleòsids | - |
dc.subject.classification | Immunodeficiència | - |
dc.subject.other | Integrase inhibitors | - |
dc.subject.other | Nucleosides | - |
dc.subject.other | Immunodeficiency | - |
dc.title | Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With HIV-1 Infection: ~5-Year Results From the LATTE-2 Study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-11-25T11:49:23Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34557563 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ofab439.pdf | 477.35 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License